<?xml version="1.0" encoding="UTF-8"?>
<p>Several studies have searched for efficient antiviral molecules that have a broad-spectrum activity inhibiting all arthritogenic alphaviruses [
 <xref rid="B240-microorganisms-07-00133" ref-type="bibr">240</xref>,
 <xref rid="B241-microorganisms-07-00133" ref-type="bibr">241</xref>,
 <xref rid="B242-microorganisms-07-00133" ref-type="bibr">242</xref>,
 <xref rid="B243-microorganisms-07-00133" ref-type="bibr">243</xref>,
 <xref rid="B244-microorganisms-07-00133" ref-type="bibr">244</xref>,
 <xref rid="B245-microorganisms-07-00133" ref-type="bibr">245</xref>,
 <xref rid="B246-microorganisms-07-00133" ref-type="bibr">246</xref>]; however, despite a long list of antivirals efficient in vitro or in vivo, no treatment is currently available [
 <xref rid="B247-microorganisms-07-00133" ref-type="bibr">247</xref>]. Indeed, all clinical trials conducted until now have either failed, such as for chloroquine [
 <xref rid="B248-microorganisms-07-00133" ref-type="bibr">248</xref>,
 <xref rid="B249-microorganisms-07-00133" ref-type="bibr">249</xref>], or have been inconclusive because of small test groups, such as for ribavirin [
 <xref rid="B250-microorganisms-07-00133" ref-type="bibr">250</xref>]. Pentosan polysulfate has shown efficiency against cartilage damage in mice both with CHIKV and RRV, and a Phase II trial is now ongoing [
 <xref rid="B251-microorganisms-07-00133" ref-type="bibr">251</xref>].
</p>
